Evidence map›Paper›PMID 38641354›Full record

ReviewThe Journal of pharmacology and experimental therapeutics2024

Recent Developments in On-Demand Voiding Therapies.

Karl B Thor, Lesley Marson, Mary A Katofiasc, Daniel J Ricca, Edward C Burgard

Erratum issuedOpen access · bronzeAbstract readReview
In one paragraph

Review in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Brain carbon monoxide can suppress the rat micturition reflex through brain γ-aminobutyric acid receptors.International journal of urology : official journal of the Japanese Urological Association · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Karl B ThorDignify Therapeutics, LLC, Durham, North Carolina kthor@dignifytherapeutics.com.ORCID 0000-0001-5482-5241
Lesley MarsonDignify Therapeutics, LLC, Durham, North Carolina.
Mary A KatofiascDignify Therapeutics, LLC, Durham, North Carolina.
Daniel J RiccaDignify Therapeutics, LLC, Durham, North Carolina.
Edward C BurgardDignify Therapeutics, LLC, Durham, North Carolina.
Dignify Therapeutics (United States) · US

Funding

Preclinical characterization of a novel neuropeptide for inducing "on-demand" voidingU44NS106685 · NINDS · DIGNIFY THERAPEUTICS, LLC · PI BURGARD, EDWARD · 2019 to 2021
$3.9M
Development of a first-in-class therapeutic for producing 'on-demand' voidingR44DK112437 · NIDDK · DIGNIFY THERAPEUTICS, LLC · PI THOR, KARL B · 2017 to 2019
$2.3M
An optimized NK2R agonist for 'on-demand' voidingR44AG055169 · NIA · DIGNIFY THERAPEUTICS, LLC · PI THOR, KARL B · 2017 to 2018
$1.8M
Delivery of peptides for inducing voiding associated with neurological retentionR42NS092178 · NINDS · DIGNIFY THERAPEUTICS, LLC · PI MARSON, LESLEY · 2016 to 2017
$1.4M
Examination of a novel therapy to induce voiding after spinal cord injuryR21NS089880 · NINDS · DIGNIFY THERAPEUTICS, LLC · PI MARSON, LESLEY · 2015 to 2016
$701k
A neurokinin receptor agonist to treat underactive bladder in the elderlyR43AG057243 · NIA · DIGNIFY THERAPEUTICS, LLC · PI THOR, KARL B · 2017 to 2017
$300k
Intrarectal mechanoreceptor sensitization to induce defecation after spinal injuryR43NS115215 · NINDS · DIGNIFY THERAPEUTICS, LLC · PI MARSON, LESLEY · 2019 to 2019
$300k
Neurokinin-2 receptor-induced micturition and defecation in aged diabetic ratsR43DK125131 · NIDDK · DIGNIFY THERAPEUTICS, LLC · PI MARSON, LESLEY · 2020 to 2020
$296k
Identification of an optimized NK2R agonist for 'on-demand' voidingR43AG055169 · NIA · DIGNIFY THERAPEUTICS, LLC · PI THOR, KARL B · 2016 to 2016
$276k
Delivery of peptides for inducing voiding associated with neurological retentionR41NS092178 · NINDS · DIGNIFY THERAPEUTICS, LLC · PI MARSON, LESLEY · 2015 to 2015
$225k
Development of a treatment for voiding dysfunction in spinal cord injured patientR43HD080263 · NICHD · DIGNIFY THERAPEUTICS, LLC · PI MARSON, LESLEY · 2014 to 2014
$159k
NIA NIH HHS R43 AG055169NIA NIH HHS R43 AG057243NIA NIH HHS R44 AG055169NICHD NIH HHS R43 HD080263NIDDK NIH HHS R43 DK125131NIDDK NIH HHS R44 DK112437NINDS NIH HHS R21 NS089880NINDS NIH HHS R41 NS092178NINDS NIH HHS R42 NS092178NINDS NIH HHS R43 NS115215NINDS NIH HHS U44 NS106685
6 · The paper itself

Abstract

One cannot survive without regularly urinating and defecating. People with neurologic injury (spinal cord injury, traumatic brain injury, stroke) or disease (multiple sclerosis, Parkinson's disease, spina bifida) and many elderly are unable to voluntarily initiate voiding. The great majority of them require bladder catheters to void urine and "manual bowel programs" with digital rectal stimulation and manual extraction to void stool. Catheter-associated urinary tract infections frequently require hospitalization, whereas manual bowel programs are time consuming (1 to 2 hours) and stigmatizing and cause rectal pain and discomfort. Laxatives and enemas produce defecation, but onset and duration are unpredictable, prolonged, and difficult to control, which can produce involuntary defecation and fecal incontinence. Patients with spinal cord injury (SCI) consider recovery of bladder and bowel function a higher priority than recovery of walking. Bladder and bowel dysfunction are a top reason for institutionalization of elderly. Surveys indicate that convenience, rapid onset and short duration, reliability and predictability, and efficient voiding are priorities of SCI individuals. Despite the severe, unmet medical need, there is no literature regarding on-demand, rapid-onset, short-duration, drug-induced voiding therapies. This article provides in-depth discussion of recent discovery and development of two candidates for on-demand voiding therapies. The first, [Lys

Indexed as

UrinationAnimalsDefecationHumansSpinal Cord Injuries

Identifiers

PMID38641354
PMCPMC11338280
OpenAlexW4394952481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.